Release Details
Voyager Therapeutics Announces Upcoming Presentations at the International Parkinson and Movement Disorder Society Virtual Congress 2020
New Phase 1b Data of Investigational Gene Therapy Compound, VY-AADC (NBIb-1817), Evaluating Three-Year Safety and Clinical Outcomes in Patients with Advanced Parkinson’s Disease
Voyager to Participate in Upcoming September Investor Conferences
- Three-Year Safety and Clinical Outcomes from the PD-1101 Trial of AADC Gene Therapy for Advanced Parkinson’s Disease
Poster #879: Update on Genetics of Movement DisordersSeptember 13, 2020 , 10:30–12:30 p.m. ET (10-minute prerecorded presentation)
- AADC Gene Therapy Administered via a Posterior Approach: 24-month Results from the PD-1102 Trial in Advanced Parkinson’s Disease
Poster #889: Poster Tour
Launches on-demand onSeptember 11, 2020 ,8:00 a.m. ET (5-minute prerecorded presentation)
Additionally, the company plans to participate in the following virtual investor conferences in September:
- Wells Fargo 2020
Virtual Healthcare Conference Wednesday, September 9 at1:20 p.m. ET Cantor Virtual Global Healthcare Conference Wednesday, September 16 at2:40 p.m. ET - Morgan Stanley 18th Annual Global Healthcare Conference
Friday, September 18 at10:15 a.m. ET
The webcast sessions may be accessed from the Investors & Media section of Voyager’s website at www.voyagertherapeutics.com. Replays of the webcasts will be archived on the Company's website for at least 30 days.
About
Investor Relations:
VP, Investor Relations
857-201-3463
pcox@vygr.com
Media:
W2Opure
949-903-4750
sseapy@purecommunications.com
Source: Voyager Therapeutics, Inc.